期刊文献+

埃博拉病毒疫苗研究进展及相关专利浅析 被引量:1

Progress of Ebola Virus Vaccines and Analysis of Related Patents
下载PDF
导出
摘要 通过非专利数据库的文献检索,总结了埃博拉病毒(EBOV)研究的最新进展,通过专利文献数据库文献检索分析EBOV疫苗的专利申请基本情况、发展趋势和技术点。结果发现专利申请量与疫情的爆发有一定的相关性;专利申请人多为政府主导的机构或非营利性机构;最新的专利申请均关注GP蛋白对病毒侵染的重要性,针对GP蛋白的抗体和疫苗正在开发中,其中Mapp生物制药公司的产品"ZMapp"作为试验性生物药物目前效果最佳。 Through searching in the non-patent database,we summarized the latest research progress of the Ebola virus ( EBOV) , and depending on the patent analysis,we have understood the basic information about the key points which the inventors focus on. It was found that the amount of patent applications and outbreaks have some correlation;the patent applicant are more for the government-led or non-profit organization;the latest patent applications were concerned about the importance of the GP protein in the virus infection, antibodies and vaccines for GP proteins are being developed,among which Mapp biopharmaceutical company’s products“Zmapp” are currently the best results as experimental biologic drugs.
出处 《生物技术进展》 2015年第2期142-147,共6页 Current Biotechnology
关键词 埃博拉病毒 疫苗 专利 ZMapp Ebola virus vaccine patent ZMapp
  • 相关文献

参考文献14

  • 1世界卫生组织.埃博拉病毒病疫情——西非[EB/OL]www.who.int/csr/don/2014_09_04-ebola/zh/,2014-09-04.
  • 2贾岩.NIH启动埃博拉病毒疫苗人体试验[N].医药经济报,2014-09-03.
  • 3Pourrut X, Kumulungui B, Wittmann T, et al.. The natural history of Ebola virus in Africa[ J ]. Microbes Infect.,2005,7 ( 7 -8) : 1005-1014.
  • 4Kuhn J H, Becker S, Ebihura H, et al.. Proposal for a revesed taxonomy of the family F-iloviridae : Clasification, names of taxas and virus abbreviations[ J] .Arch. Virol. ,2010,155(12) : 2083 -2013.
  • 5Ascenzi P, Bocedi A, Heptonastall J, et al.. Ebelavirus and Marburgvirus: Insight the Filoviridae family [ J ]. Mol. Aspects Med. ,2008,29(3) : 151-185.
  • 6Nanba A, Imai M, Watanabe S, et al.. Ebolavirus is internalized into host cell v/a macro-pinocytosis in a viral glycoprotein-dependent manner [ J ]. Proc. Nail. Acad. Sci. USA,2008,105(4) : 1129-1133.
  • 7Lopez L A, Yang S J, Hauser H, et al.. Ebola virus glycopretein counteracts BST-2,/Tetherin restriction in a sequence- independent manner that does not require tetherin surface removal[ J] .J. Virol. ,2010,84(14) :7243-7255.
  • 8Falzarano D, Krokbin O, Wahl-Jensen V, et al.. Structure- function analysis of the soluble glycoprotein, sGP, of Ebolavirus[ J ]. Chem. Biochem., 2006,454 ( 7201 ) : 177-182.
  • 9Reynard O, Borowiak M, Volchkova V A, et al.. Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface protein [ J ]. J. Virol., 2009,83 ( 18 ) : 9596 -9601.
  • 10Ou W, Delisle J, Konduro K, et al.. Development and characterization of rabbit and mouse antibodies against ebolavims envelope glycoprotein [ J ]. J. Virol. Methods, 2011, 174(1-2) :99-109.

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部